{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:54:22Z","timestamp":1774882462793,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The ancillary study described in this manuscript was done without any type of funding. Data collection were supported by an unrestricted grant from Pfzer, Novartis, Janssen, and Abbvie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05237-7","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T09:03:57Z","timestamp":1667639037000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-391X","authenticated-orcid":false,"given":"N. El","family":"Ouardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0668-5680","authenticated-orcid":false,"given":"A. El","family":"Maghraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-1967","authenticated-orcid":false,"given":"H. J.","family":"Djossou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-0174","authenticated-orcid":false,"given":"L.","family":"Taoubane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-7729","authenticated-orcid":false,"given":"A. M.","family":"Ghassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2062-8877","authenticated-orcid":false,"given":"H.","family":"Toufik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-1354","authenticated-orcid":false,"given":"A.","family":"Majjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sadni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mounach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-5034","authenticated-orcid":false,"given":"I.","family":"Hmamouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-4341","authenticated-orcid":false,"given":"R.","family":"Abouqal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1750","authenticated-orcid":false,"given":"R.","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9847-2142","authenticated-orcid":false,"given":"F.","family":"Allali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-3407","authenticated-orcid":false,"given":"I. El","family":"Bouchti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-4173","authenticated-orcid":false,"given":"I.","family":"Ghozlani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4190-1481","authenticated-orcid":false,"given":"H.","family":"Hassikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-4391","authenticated-orcid":false,"given":"T.","family":"Harzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2733-5594","authenticated-orcid":false,"given":"L.","family":"Ichchou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-8479","authenticated-orcid":false,"given":"O.","family":"Mkinsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-2532","authenticated-orcid":false,"given":"R.","family":"Niamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"5237_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1060028016682330","volume":"51","author":"MH Garc\u00eda-Lagunar","year":"2017","unstructured":"Garc\u00eda-Lagunar MH, Guti\u00e9rrez-C\u00edvicos MR, Garc\u00eda-Sim\u00f3n MS, Conesa-Zamora P, Jimenez-Santos E, Cano-Vivar P et al (2017) Reasons for discontinuation and adverse effects of TNF\u03b1 inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. Ann Pharmacother 51:388\u2013393. https:\/\/doi.org\/10.1177\/1060028016682330","journal-title":"Ann Pharmacother"},{"key":"5237_CR2","first-page":"57","volume":"44","author":"JL Gomes","year":"2019","unstructured":"Gomes JL, Sepriano A, Eus\u00e9bio M, Serra S, Fonseca JE, Saavedra MJ et al (2019) Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. Acta Reumatol Port 44:57\u201364","journal-title":"Acta Reumatol Port"},{"key":"5237_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1590\/S1518-8787.2016050006265","volume":"50","author":"MA\u00c1 de Machado","year":"2016","unstructured":"de Machado MA\u00c1, de Moura CS, Ferr\u00e9 F, Bernatsky S, Rahme E, de Acurcio FA (2016) Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica 50:50. https:\/\/doi.org\/10.1590\/S1518-8787.2016050006265","journal-title":"Rev Saude Publica"},{"key":"5237_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/13696998.2019.1571498","volume":"22","author":"A Shahabi","year":"2019","unstructured":"Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A et al (2019) The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients. J Med Econ 22:350\u2013358. https:\/\/doi.org\/10.1080\/13696998.2019.1571498","journal-title":"J Med Econ"},{"key":"5237_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.46497\/ArchRheumatol.2020.7499","volume":"35","author":"M Sebastiani","year":"2020","unstructured":"Sebastiani M, Manfredi A, Iannone F, Gremese E, Bortoluzzi A, Favalli E et al (2020) Factors predicting early failure of etanercept in rheumatoid arthritis: an analysis from the gruppo Italiano di studio sulla early arthritis (Italian group for the study of early arthritis) registry. Arch Rheumatol 35:163\u2013169. https:\/\/doi.org\/10.46497\/ArchRheumatol.2020.7499","journal-title":"Arch Rheumatol"},{"key":"5237_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-05624-0","volume":"20","author":"T Du Toit","year":"2020","unstructured":"Du Toit T, Esterhuizen TM, Tiffin N, Abulfathi AA, Reuter H, Decloedt EH (2020) Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018. BMC Infect Dis 20:1\u20138. https:\/\/doi.org\/10.1186\/s12879-020-05624-0","journal-title":"BMC Infect Dis"},{"key":"5237_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90442-w","author":"A Prior-Espa\u00f1ol","year":"2021","unstructured":"Prior-Espa\u00f1ol A, S\u00e1nchez-Piedra C, Campos J, Manero FJ, P\u00e9rez-Garc\u00eda C, Boh\u00f3rquez C et al (2021) Clinical factors associated with discontinuation of ts\/bDMARDs in rheumatic patients from the BIOBADASER III registry. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-90442-w","journal-title":"Sci Rep"},{"key":"5237_CR8","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1136\/ejhpharm-2019-002133","volume":"28","author":"M Samart\u00edn-Ucha","year":"2021","unstructured":"Samart\u00edn-Ucha M, Pego-Reigosa JM, \u00c1lvarez-Payero M, Martin-Vila A, Pineiro-Corrales G, Rodriguez-Rodriguez M et al (2021) Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study. Eur J Hosp Pharm 28:E47-50. https:\/\/doi.org\/10.1136\/ejhpharm-2019-002133","journal-title":"Eur J Hosp Pharm"},{"key":"5237_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","volume":"4","author":"V Strand","year":"2017","unstructured":"Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J (2017) discontinuation of biologic therapy in rheumatoid arthritis: analysis from the corrona RA registry. Rheumatol Ther 4:489\u2013502. https:\/\/doi.org\/10.1007\/s40744-017-0078-y","journal-title":"Rheumatol Ther"},{"key":"5237_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/RHU.0000000000000741","volume":"25","author":"P Chiowchanwisawakit","year":"2019","unstructured":"Chiowchanwisawakit P, Katchamart W, Osiri M, Narongroeknawin P, Chevaisrakul P, Kitumnuaypong T et al (2019) Effectiveness and drug survival of anti-tumor necrosis factor therapies in patients with spondyloarthritis: analysis from the thai rheumatic disease prior authorization registry. J Clin Rheumatol 25:9\u201315. https:\/\/doi.org\/10.1097\/RHU.0000000000000741","journal-title":"J Clin Rheumatol"},{"key":"5237_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061506","author":"E Piragine","year":"2022","unstructured":"Piragine E, Petri D, Martelli A, Janowska A, Dini V, Romanelli M et al (2022) Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11061506","journal-title":"J Clin Med"},{"key":"5237_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/rheumatology\/kev374","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, G\u00f3mez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (United Kingdom) 55:523\u2013534. https:\/\/doi.org\/10.1093\/rheumatology\/kev374","journal-title":"Rheumatology (United Kingdom)"},{"key":"5237_CR13","doi-asserted-by":"publisher","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","volume":"3","author":"V Navarro-Comp\u00e1n","year":"2017","unstructured":"Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, de Miguel E, Diaz del Campo P, Balsa A, Gratac\u00f3s J (2017) Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open 3:e000524. https:\/\/doi.org\/10.1136\/rmdopen-2017-000524","journal-title":"RMD Open"},{"key":"5237_CR14","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","volume":"40","author":"M Lorenzin","year":"2021","unstructured":"Lorenzin M, Ortolan A, Cozzi G, Calligaro A, Favaro M, del Ross T et al (2021) Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15\u00a0year monocentric real-life study. Clin Rheumatol 40:4569\u20134580. https:\/\/doi.org\/10.1007\/s10067-021-05799-0","journal-title":"Clin Rheumatol"},{"key":"5237_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04075-0","author":"K Ebina","year":"2022","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2022) Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-04075-0","journal-title":"Sci Rep"},{"key":"5237_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1684-0","author":"T Wilke","year":"2017","unstructured":"Wilke T, Mueller S, Lee SC, Majer I, Heisen M (2017) Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. BMC Musculoskelet Disord. https:\/\/doi.org\/10.1186\/s12891-017-1684-0","journal-title":"BMC Musculoskelet Disord"},{"key":"5237_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/03009742.2020.1855365","volume":"50","author":"ME D\u2019Amico","year":"2021","unstructured":"D\u2019Amico ME, Silvagni E, Carrara G, Zanetti A, Govoni M, Scir\u00e8 CA et al (2021) Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RE cord-linkage on rheumatic disease study on administrative healthcare databases. Scand J Rheumatol 50:333\u2013342. https:\/\/doi.org\/10.1080\/03009742.2020.1855365","journal-title":"Scand J Rheumatol"},{"key":"5237_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/rheumatology\/kez221","volume":"58","author":"K Lauper","year":"2019","unstructured":"Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK et al (2019) Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology (United Kingdom) 58:2221\u20132229. https:\/\/doi.org\/10.1093\/rheumatology\/kez221","journal-title":"Rheumatology (United Kingdom)"},{"key":"5237_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/JCMA.0000000000000673","volume":"85","author":"CC Wang","year":"2022","unstructured":"Wang CC, Tseng K, sen, Tsao YP, Chen WS, Lai CC, Sun YS, et al (2022) Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: A two-center study in Taiwan. J Chin Med Assoc 85:175\u2013182. https:\/\/doi.org\/10.1097\/JCMA.0000000000000673","journal-title":"J Chin Med Assoc"},{"key":"5237_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar3369","journal-title":"Arthritis Res Ther"},{"key":"5237_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.708168","author":"V Bhushan","year":"2021","unstructured":"Bhushan V, Lester S, Briggs L, Hijjawi R, Shanahan EM, Pontifex E et al (2021) Real-Life retention rates and reasons for switching of biological dmards in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2021.708168","journal-title":"Front Med (Lausanne)"},{"key":"5237_CR22","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/S10067-020-05567-6","volume":"40","author":"E Van Mulligen","year":"2021","unstructured":"Van Mulligen E, Ahmed S, Weel AEAM, Hazes JMW, van der Helm- van Mil AHM, de Jong PHP. (2021) Factors that influence biological survival in rheumatoid arthritis: results of a real-world academic cohort from the Netherlands. Clin Rheumatol 40:2177\u20132183. https:\/\/doi.org\/10.1007\/S10067-020-05567-6","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05237-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:10:33Z","timestamp":1673608233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05237-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["5237"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05237-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol for the original RBSMR study was reviewed and approved by local institutional review boards and the national ethic committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}